Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players
Metrics: PDF 776 views | HTML 1258 views | ?
Sara Franceschi1, Francesca Lessi1, Paolo Aretini1, Valerio Ortenzi2, Cristian Scatena2, Michele Menicagli1, Marco La Ferla1, Prospero Civita1, Katia Zavaglia3, Claudia Scopelliti1, Alessandro Apollo4, Francesco Giovanni Carbone2, Riccardo Vannozzi5, Generoso Bevilacqua6, Francesco Pasqualetti7, Antonio Giuseppe Naccarato2 and Chiara Maria Mazzanti1
1Fondazione Pisana per la Scienza, Onlus, Pisa, Italy
2Department of Translational Research and New Technologies in Medicine, University Hospital of Pisa, Pisa, Italy
3SOD Molecular Genetics, University Hospital of Pisa, Pisa, Italy
4Tumor Cell Biology Unit, Istituto Tumori Toscana, Florence, Italy
5Neurosurgery Department, University Hospital of Pisa, Pisa, Italy
6Pathological Anatomy Section, San Rossore Clinic, Pisa, Italy
7Radiotherapy Department, University Hospital of Pisa, Pisa, Italy
Chiara Maria Mazzanti, email: firstname.lastname@example.org
Keywords: glioblastoma; next generation sequencing (NGS); recurrence free survival (RFS); onco-drivers; tumor suppressors
Received: November 17, 2017 Accepted: April 02, 2018 Published: May 08, 2018
Glioblastoma is a devastating disease that despite all the information gathered so far, its optimal management remains elusive due to the absence of validated targets from clinical studies. A better clarification of the molecular mechanisms is needed. In this study, having access to IDH1 wild-type glioblastoma of patients with exceptionally long recurrence free survival (RFS), we decided to compare their mutational and gene expression profile to groups of IDH1 wild-type glioblastoma of patients with shorter RFS, by using NGS technology. The exome analysis revealed that Long-RFS tumors have a lower mutational rate compared to the other groups. A total of 158 genes were found differentially expressed among the groups, 112 of which distinguished the two RFS extreme groups. Overall, the exome data suggests that shorter RFS tumors could be, chronologically, in a more advanced state in the muli-step tumor process of sequential accumulation of mutations. New players in this kind of cancer emerge from the analysis, confirmed at the RNA/DNA level, identifying, therefore, possible oncodrivers or tumor suppressor genes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.